Naltos™, an innovative and rapid approach to treating breakthrough pain using a novel pain relief peptide
Naltos™, an innovative and rapid approach to treating breakthrough pain using a novel pain relief peptide
批准号:
133693
负责人:
金额:
$11.33万
依托单位:
依托单位国家:
英国
项目类别:
Feasibility Studies
财政年份:
2019
资助国家:
英国
项目状态:
已结题
起止时间:
2019 至 --
中文摘要
“在英国,大约43%的人,即大约2800万成年人经历过疼痛,这比患有糖尿病、心脏病和癌症的人加起来还要多。75岁或以上的成年人(62%)比18至25岁的成年人(14.3%)有更多的疼痛经历([https://goo.gl/QvWaW5][0]])。仅背痛一项每年就花费NHS 123亿英镑;考虑到医疗费用、收入损失和生产力损失,不受控制的疼痛是一种严重且治疗不足的疾病,对英国经济造成的损失要大得多。镇痛药是治疗癌痛的一线疗法;然而,最近由于药物滥用和过量使用,芬太尼等阿片类止痛药出现了反弹。在过去的8个月里,英国至少有60例毒品死亡与芬太尼有关([https://goo.gl/iVs1eG][1]])。Alchemy Pharmatech正在与制药纳米技术专家Nanomerics合作,以证明NaltosTM的可行性。NaltosTM是一种紧凑、谨慎和廉价的新型鼻内给药系统,用于快速给药干粉类药物。成功的项目交付将使Nanomerics公司受益,为他们目前和未来的药物提供有效的鼻子到大脑的输送系统,从而增强他们的竞争优势,增加收入,从而推动两家公司吸引更多的资金来开发进一步的产品。[0] https://goo.gl/QvWaW5 [1]: https://goo.gl/iVs1eG”
英文摘要
"Approximately 43% of people in the UK, or around 28 million adults experience pain, which is more than the combined total of those suffering with diabetes, heart disease and cancer. More adults aged 75 or over (62%) experienced pain than those aged 18 to 25 (14.3%) ([https://goo.gl/QvWaW5][0]). Back pain alone costs the NHS £12.3 billion per year; a serious and undertreated condition, uncontrolled pain costs the UK economy far more when considering healthcare expenses, lost income and lost productivity.Analgesics are the frontline therapy for the treatment of cancer pain; however, there has been a recent backlash against opioid-based painkillers, such as fentanyl, due to drug abuse and overdosing. At least 60 drugs deaths in the UK in the past eight months have been linked to fentanyl ([https://goo.gl/iVs1eG][1]).Alchemy Pharmatech is partnering with Nanomerics, specialists in pharmaceutical nanotechnology, to demonstrate feasibility of NaltosTM, a compact, discreet and inexpensive novel intranasal delivery system for quick onset delivery of dry powder-based medications.Successful project delivery will benefit Nanomerics by providing an effective nose-to-brain delivery system for their range of current and future pipeline drugs, thereby enhancing their competitive advantage and increasing revenue and thus, propel both companies in their aim to attract additional funding to develop further products.[0]: https://goo.gl/QvWaW5[1]: https://goo.gl/iVs1eG"
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金